Literature DB >> 18317232

Carnitine supplementation induces acylcarnitine production in tissues of very long-chain acyl-CoA dehydrogenase-deficient mice, without replenishing low free carnitine.

Sonja Primassin1, Frank Ter Veld, Ertan Mayatepek, Ute Spiekerkoetter.   

Abstract

Deficiency of very long-chain acyl-CoA dehydrogenase (VLCAD) results in accumulation of C14-C18 acylcarnitines and low free carnitine. Carnitine supplementation is still controversial. VLCAD knockout (VLCAD(+/-)) mice exhibit a similar clinical and biochemical phenotype to those observed in humans. VLCAD(+/-) mice were fed with carnitine dissolved in drinking water. Carnitine, acylcarnitines, and gamma-butyrobetaine were measured in blood and tissues. Measurements were performed under resting conditions, after exercise and after 24 h of regeneration. HepG2 cells were incubated with palmitoyl-CoA and palmitoyl-carnitine, respectively, to examine toxicity. With carnitine supplementation, acylcarnitine production was significantly induced. Nevertheless, carnitine was low in skeletal muscle after exercise. Without carnitine supplementation, liver carnitine significantly increased after exercise, and after 24 h of regeneration, carnitine concentrations in skeletal muscle completely replenished to initial values. Incubation of hepatic cells with palmitoyl-CoA and palmitoyl-carnitine revealed a significantly reduced cell viability after incubation with palmitoyl-carnitine. The present study demonstrates that carnitine supplementation results in significant accumulation of potentially toxic acylcarnitines in tissues. The expected prevention of low tissue carnitine was not confirmed. The principle mechanism regulating carnitine homeostasis seems to be endogenous carnitine biosynthesis, also under conditions with increased demand of carnitine such as in VLCAD-deficiency.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18317232     DOI: 10.1203/PDR.0b013e31816ff6f0

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  24 in total

Review 1.  Mitochondrial fatty acid oxidation disorders: pathophysiological studies in mouse models.

Authors:  Ute Spiekerkoetter; Philip A Wood
Journal:  J Inherit Metab Dis       Date:  2010-06-08       Impact factor: 4.982

2.  Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop.

Authors:  U Spiekerkoetter; M Lindner; R Santer; M Grotzke; M R Baumgartner; H Boehles; A Das; C Haase; J B Hennermann; D Karall; H de Klerk; I Knerr; H G Koch; B Plecko; W Röschinger; K O Schwab; D Scheible; F A Wijburg; J Zschocke; E Mayatepek; U Wendel
Journal:  J Inherit Metab Dis       Date:  2009-04-28       Impact factor: 4.982

3.  Pre-exercise medium-chain triglyceride application prevents acylcarnitine accumulation in skeletal muscle from very-long-chain acyl-CoA-dehydrogenase-deficient mice.

Authors:  Sonja Primassin; Sara Tucci; Diran Herebian; Annette Seibt; Lars Hoffmann; Frank ter Veld; Ute Spiekerkoetter
Journal:  J Inherit Metab Dis       Date:  2010-05-06       Impact factor: 4.982

4.  Effect of carnitine, acetyl-, and propionylcarnitine supplementation on the body carnitine pool, skeletal muscle composition, and physical performance in mice.

Authors:  Réjane Morand; Jamal Bouitbir; Andrea Felser; Jürgen Hench; Christoph Handschin; Stephan Frank; Stephan Krähenbühl
Journal:  Eur J Nutr       Date:  2013-12-11       Impact factor: 5.614

5.  CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity.

Authors:  Naoto Fujiwara; Hayato Nakagawa; Kenichiro Enooku; Yotaro Kudo; Yuki Hayata; Takuma Nakatsuka; Yasuo Tanaka; Ryosuke Tateishi; Yohko Hikiba; Kento Misumi; Mariko Tanaka; Akimasa Hayashi; Junji Shibahara; Masashi Fukayama; Junichi Arita; Kiyoshi Hasegawa; Hadassa Hirschfield; Yujin Hoshida; Yoshihiro Hirata; Motoyuki Otsuka; Keisuke Tateishi; Kazuhiko Koike
Journal:  Gut       Date:  2018-02-06       Impact factor: 23.059

Review 6.  Current issues regarding treatment of mitochondrial fatty acid oxidation disorders.

Authors:  Ute Spiekerkoetter; Jean Bastin; Melanie Gillingham; Andrew Morris; Frits Wijburg; Bridget Wilcken
Journal:  J Inherit Metab Dis       Date:  2010-09-10       Impact factor: 4.982

7.  Sirt3 promotes the urea cycle and fatty acid oxidation during dietary restriction.

Authors:  William C Hallows; Wei Yu; Brian C Smith; Mark K Devries; Mark K Devires; James J Ellinger; Shinichi Someya; Michael R Shortreed; Tomas Prolla; John L Markley; Lloyd M Smith; Shimin Zhao; Kun-Liang Guan; John M Denu
Journal:  Mol Cell       Date:  2011-01-21       Impact factor: 17.970

8.  Corresponding increase in long-chain acyl-CoA and acylcarnitine after exercise in muscle from VLCAD mice.

Authors:  Frank ter Veld; Sonja Primassin; Lars Hoffmann; Ertan Mayatepek; Ute Spiekerkoetter
Journal:  J Lipid Res       Date:  2008-10-31       Impact factor: 5.922

9.  Acute dilated cardiomyopathy in a patient with deficiency of long-chain 3-hydroxyacyl-CoA dehydrogenase.

Authors:  Peter C Dyke; Laura Konczal; Dennis Bartholomew; Kim L McBride; Timothy M Hoffman
Journal:  Pediatr Cardiol       Date:  2008-12-16       Impact factor: 1.655

10.  Management and outcome in 75 individuals with long-chain fatty acid oxidation defects: results from a workshop.

Authors:  U Spiekerkoetter; M Lindner; R Santer; M Grotzke; M R Baumgartner; H Boehles; A Das; C Haase; J B Hennermann; D Karall; H de Klerk; I Knerr; H G Koch; B Plecko; W Röschinger; K O Schwab; D Scheible; F A Wijburg; J Zschocke; E Mayatepek; U Wendel
Journal:  J Inherit Metab Dis       Date:  2009-04-29       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.